VSY Biotechnology GmbH announced it has been granted a U.S. patent from the United States Patent and Trademark Office for its Sinusoidal Vision Technology (SVT), designed to provide spectacle-free vision for cataract patients.
Give me some background on the company.
Based in Germany, VSY Biotechnology is focused on cataract products and developing advancements for existing intraocular lenses (IOLs) with its novel platforms as well as foldable scleral fixation lens, injector and cartridge systems, and viscoelastic for cataract surgery.
Now tell me about SVT.
SVT is a unique, patent technique for producing an IOL optical surface with no sharp edges to provide the best optical performance in trifocal IOL design.
The shape of the lens is based on sinusoidal functions—leading to smooth and varying surface profiles—and achieving continuous vision.
What else?
The technology operates in tandem with VSY’s Acriva Trinova Pro C Pupil Adaptive—the first and only sinusoidal trifocal IOL that combines with pupil adaptive design.
Exactly how do these technologies work together?
With the help of SVT, the Acriva Trinova Pro C Pupil Adaptive delivers effective and efficient light energy between three foci based on light conditions and pupil sizes in order to maximize the wide visual range.
What else should we know about this technology?
Outside of the United States, SVT has already received validation from 11 European countries and patents in countries including China and Russia.
Significance?
As a spectacle-free vision option for cataract patients, SVT has the potential to enhance their quality of life and provide an alternative solution to traditional trifocal IOLs.